Leducq Foundation provides $7 million to support Cardiac Splicing as a Therapeutic Target project
Diverse messenger RNAs are produced in cells by “alternative splicing.” The Leducq Foundation is now supporting a transatlantic network dedicated to investigating this process in heart muscle cells and how changes in this process contribute to disease. Professor Michael Gotthardt of the MDC and Professor Leslie Leinwand of the University of Colorado Boulder are coordinating the project.
Despite advances in prevention and therapy, cardiovascular diseases are still one of the leading causes of death worldwide. Scientists have only recently begun to understand the key role of alternative splicing - the stitching together of messenger RNA during gene transcription - in cardiovascular diseases. The Leducq Foundation is providing 7 million U.S. dollars over the next five years to support the Cardiac Splicing as a Therapeutic Target (CASTT) project, which is comprised of six European a
$7 million to advance cardiovascular research
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Can rapid antigen tests help screen for COVID-19?
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body s immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor. These results confirm that therapeutic vaccines or immunotherapies are more effective against brain tumors if active substances are simultaneously used to promote the suppressed immune system.